Recent research have converged on the convergence of GLP-1|GIP|GCGR activator therapies and dopamine communication. While GCGR activators are increasingly employed for addressing type 2 T2DM, their emerging impacts on reinforcement circuits, specifically influenced by dopamine networks, are gaining significant focus. This report provides a summary